SCHEMBL4591840

SCHEMBL4591840

OCC1CCCN(Cc2ccc(Br)cc2)C1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.70
LTA4H P09960 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
MAPT P10636 1/20 0.48
ALDH1A1 P00352 2/20 0.48
TNIK Q9UKE5 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
HTT P42858 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
GAA P10253 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDE2A O00408 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5424601 1.00 CYP2D6 (0.70) CYP2D6LTA4HMEN1KMT2AMAPT
SCHEMBL5431804 1.00 CYP2D6 (0.70) CYP2D6LTA4HMEN1KMT2AMAPT
SCHEMBL5418095 0.91 CYP2D6 (0.57) CYP2D6LTA4HMEN1KMT2AALDH1A1
SCHEMBL6267504 0.86 CYP2D6 (0.72) CYP2D6LTA4HKMT2AMAPTALDH1A1
SCHEMBL4264871 0.85 CYP2D6 (0.70) CYP2D6LTA4HMAPTALDH1A1HTT
SCHEMBL7071972 0.84 CYP2D6 (0.83) CYP2D6LTA4HALDH1A1BCHEACHE
SCHEMBL1944588 0.84 CYP2D6 (0.83) CYP2D6LTA4HALDH1A1BCHEACHE
SCHEMBL24023628 0.82 CYP2D6 (1.00) CYP2D6LTA4HMEN1KMT2AALDH1A1
SCHEMBL8326768 0.82 CYP2D6 (0.66) CYP2D6LTA4HMEN1KMT2AMAPT
SCHEMBL1427977 0.81 ALDH1A1 (0.71) LTA4HMEN1KMT2AALDH1A1TNIK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101296906-A (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INT (DE) 2008-10-29 CN disclosed
EP-1943231-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-16 EP disclosed
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds ROTH GERALD J 2007-05-17 US disclosed
WO-2007048802-A1 (HETERO)ARYL COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111981-A1 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 CYP2D6 547/4885LTA4H 1868/4885MEN1 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.